Victory Financial Group LLC Buys 2,768 Shares of AbbVie Inc. $ABBV

Victory Financial Group LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 31.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,631 shares of the company’s stock after buying an additional 2,768 shares during the period. Victory Financial Group LLC’s holdings in AbbVie were worth $3,042,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Ranch Capital Advisors Inc. increased its holdings in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its position in shares of AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $23,557,000. Wedge Capital Management L L P NC boosted its stake in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, State Street Corp grew its position in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of research analyst reports. Argus lifted their price target on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. HSBC increased their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Finally, Oppenheimer upped their target price on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $279.86.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a biologics license application to the FDA for etentamig, a next-generation BCMA×CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, the treatment significantly improved overall response rate and progression-free survival versus available standard therapies, supporting potential pipeline diversification beyond immunology. AbbVie Submits BLA for Etentamig
• Positive Sentiment: The FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease, including an on-body injector that enables an at-home treatment start. The approval could improve patient convenience and help support continued growth of AbbVie’s key immunology franchise. FDA Approves SKYRIZI Crohn’s Disease Regimen
• Positive Sentiment: Goldman Sachs raised its AbbVie price target to $294, while reports that Citadel has built an approximately $900 million position may reinforce institutional confidence. Analysts also identify SKYRIZI and RINVOQ as important growth drivers.
• Neutral Sentiment: Options markets imply an approximately 5% potential move around the October 30 earnings release. AbbVie previously exceeded quarterly EPS and revenue expectations, but investors will focus on SKYRIZI and RINVOQ sales, expenses and updated guidance.
• Negative Sentiment: Some analysts view ABBV as fully valued after its strong run, with rising expenses, declining estimates and intensifying competition creating near-term risks. Erste Group Bank also reduced its EPS forecast, potentially limiting upside ahead of earnings.

AbbVie Price Performance

ABBV stock opened at $286.70 on Wednesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The stock’s 50 day simple moving average is $267.66 and its 200 day simple moving average is $236.20.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.